Advice
in the absence of a submission from the holder of the marketing authorisation:
ruxolitinib (Jakavi®) is not recommended for use within NHSScotland.
Indication under review: for the treatment of:
- patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids
- patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice620KB (PDF)
Medicine details
- Medicine name:
- ruxolitinib (Jakavi®)
- SMC ID:
- SMC2498
- Indication:
for the treatment of:
- patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids
- patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 June 2022